Recent Advances in the Treatment of Peripheral T‐Cell Lymphoma

摘要: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of clinically aggressive diseases associated with poor outcome. Despite progress in the last several years, resulting deeper understanding natural history and biology PTCL based on molecular profiling next-generation sequencing, there need for improvement efficacy chemotherapeutic regimens newly diagnosed patients. Treatment front-line setting most often cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or CHOP-like regimens, which are high failure rate frequent relapses. Trials evaluating intensive chemotherapy have resulted variable success prolonging event-free survival, but overall survival has remained unchanged. Furthermore, this strategy limited to patients who complete remission after initial anthracycline-based chemotherapy. Many ineligible hematopoietic stem cell transplantation because age achieve remission. For relapsed disease, advances been made therapeutic arsenal PTCL. New drugs investigated phase II studies achieved response rates between 10% 30%. However, date identification new therapies largely empiric, long-term remissions exception rule. Current patient outcomes suggest development active biologically rational improve disease management extend duration iterative biomarker evaluation. This review covers focuses agents combinations, better pathogenesis disease. Implications practice Recent peripheral led emergence drugs. Unfortunately, not met similar outcome improvement. Anthracycline-containing mostly (CHOP), considered standard care, although best first-line approach remains be defined. In refractory settings, 30%, these do significantly affect rates. Therapeutic options characterization various histological types combinations CHOP regimen synergic may lead outcomes.